Sino Biopharmaceutical’s New Drug Application Accepted for Advanced Cancer Treatment
Company Announcements

Sino Biopharmaceutical’s New Drug Application Accepted for Advanced Cancer Treatment

Sino Biopharmaceutical (HK:1177) has released an update.

Sino Biopharmaceutical has announced the acceptance of a new drug application for Anlotinib Hydrochloride Capsules combined with chemotherapy, marking a significant step in treating advanced soft tissue sarcoma. This innovative combination therapy has shown promising efficacy in clinical trials, potentially offering hope to patients less responsive to conventional treatments. The company’s ongoing investment in research and development underscores its commitment to advancing cancer treatment options.

For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskSino Biopharm’s Garsorasib Gains Approval in China
TipRanks HongKong Auto-Generated NewsdeskSino Biopharmaceutical Sees Strong Q3 Financial Growth
TipRanks HongKong Auto-Generated NewsdeskSino Biopharmaceutical to Boost Market Share through Strategic Acquisitions
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App